Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the registration of its phagogram as an in vitro diagnostic test (“Phagogram 1.5”) […]
Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other […]
Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with Ovid Therapeutics. Under the terms of the collaboration, Gensaic will exclusively develop phage-derived gene […]
A genome engineering-based systematic strategy for developing phage resistant Escherichia coli strains has been successfully developed through the collaborative efforts of a team led by Professor Sang Yup Lee, Professor Shi Chen, and Professor Lianrong […]
For the first time, scientists have designed a phage combination therapy that can precisely target and suppress gut bacteria associated with inflammatory bowel diseases (IBD). Presented on August 4 in the journal Cell, the work […]
New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mBio, an open access journal of the American Society for Microbiology. In recent […]
Since first discovered in the 1980s, retrons have puzzled researchers who simply wanted to know what these bacterial DNA sequences actually did. Now, EMBL scientists have identified that some retrons encode toxin proteins, which they […]
The communities formed by human gut microbes can now be predicted more accurately with a new computer model developed in a collaboration between biologists and engineers, led by the University of Michigan and the University […]
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its highly productive bacterial Mimicry drug discovery platform, today announces that it has signed a strategic R&D collaboration and license agreement with Nestlé […]
Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like […]
Changes in the way that humans live and eat have resulted in tremendous alterations in the gut microbiome, especially over the past few decades. These changes have been linked to increased rates of asthma, allergies, […]